AU2012347997B2 - Oral spray formulations and methods for administration of sildenafil - Google Patents

Oral spray formulations and methods for administration of sildenafil Download PDF

Info

Publication number
AU2012347997B2
AU2012347997B2 AU2012347997A AU2012347997A AU2012347997B2 AU 2012347997 B2 AU2012347997 B2 AU 2012347997B2 AU 2012347997 A AU2012347997 A AU 2012347997A AU 2012347997 A AU2012347997 A AU 2012347997A AU 2012347997 B2 AU2012347997 B2 AU 2012347997B2
Authority
AU
Australia
Prior art keywords
sildenafil
dose
spray
formulation
test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012347997A
Other languages
English (en)
Other versions
AU2012347997A1 (en
Inventor
David Bergstrom
Foye Opawale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SUDA Ltd
Original Assignee
SUDA Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SUDA Ltd filed Critical SUDA Ltd
Publication of AU2012347997A1 publication Critical patent/AU2012347997A1/en
Assigned to SUDA LIMITED reassignment SUDA LIMITED Amend patent request/document other than specification (104) Assignors: DAVID BERGSTROM, FOYE OPAWALE, SUDA LIMITED
Application granted granted Critical
Publication of AU2012347997B2 publication Critical patent/AU2012347997B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012347997A 2011-12-05 2012-12-04 Oral spray formulations and methods for administration of sildenafil Ceased AU2012347997B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161566879P 2011-12-05 2011-12-05
US61/566,879 2011-12-05
PCT/US2012/067763 WO2013085904A1 (en) 2011-12-05 2012-12-04 Oral spray formulations and methods for administration of sildenafil

Publications (2)

Publication Number Publication Date
AU2012347997A1 AU2012347997A1 (en) 2014-07-03
AU2012347997B2 true AU2012347997B2 (en) 2017-07-20

Family

ID=47430090

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012347997A Ceased AU2012347997B2 (en) 2011-12-05 2012-12-04 Oral spray formulations and methods for administration of sildenafil

Country Status (13)

Country Link
US (1) US9186321B2 (cg-RX-API-DMAC7.html)
EP (1) EP2787967B1 (cg-RX-API-DMAC7.html)
JP (1) JP6047174B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140117360A (cg-RX-API-DMAC7.html)
CN (1) CN104822368B (cg-RX-API-DMAC7.html)
AU (1) AU2012347997B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014013650A2 (cg-RX-API-DMAC7.html)
CA (1) CA2858364C (cg-RX-API-DMAC7.html)
IL (1) IL232970A0 (cg-RX-API-DMAC7.html)
RU (1) RU2611403C1 (cg-RX-API-DMAC7.html)
SG (1) SG11201402938RA (cg-RX-API-DMAC7.html)
WO (1) WO2013085904A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201404091B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015070049A1 (en) * 2013-11-08 2015-05-14 Insys Pharma, Inc. Sildenafil sublingual spray formulation
NO2723977T3 (cg-RX-API-DMAC7.html) 2014-03-19 2018-03-10
DK3277283T3 (da) 2015-04-03 2021-04-12 Benuvia Therapeutics Llc Sublinguale sildenafilsprayformuerlinger
US10111833B2 (en) 2015-04-03 2018-10-30 Insys Development Company, Inc. Sildenafil sublingual spray formulations
BR102015020720A2 (pt) * 2015-08-27 2017-03-01 Henrique Leonardo Pereira Luis composição hidrofíilica atóxica, bioidêntica e biodegradável à base de partículas micronizadas de acido hialurônico, com propriedades mucoadesivas e carreadoras via transmucosa aglutinadas por bioengenharia a um ipde5, para tratamento de disfunção erétil, com aplicação em sistema de spray de aerossol sublingual
WO2018070971A1 (ru) * 2016-10-10 2018-04-19 Товарыство З Обмэжэною Видповидальнистю Науково-Выробныча Фирма "Микрохим" Фармацевтическая композиция в форме оромукозного спрея для лечения эректильной дисфункции и легочной артериальной гипертензии
CA3041112A1 (en) * 2016-10-31 2018-05-03 Suda Ltd Mucosal active agent delivery
US20220395559A1 (en) * 2019-11-07 2022-12-15 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN111110633B (zh) * 2020-01-21 2022-12-02 合肥医工医药股份有限公司 一种他达拉非喷雾剂及其制备方法
CA3200648A1 (en) * 2020-12-04 2022-06-09 Paul Bundschuh Therapeutic material with low ph and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035926A2 (en) * 1999-11-18 2001-05-25 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
US20050142069A1 (en) * 1997-10-01 2005-06-30 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20070031349A1 (en) * 2005-06-23 2007-02-08 David Monteith Rapidly absorbing oral formulations of PDE 5 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
DE19834506A1 (de) 1998-07-31 2000-02-03 Hexal Ag Transmucosales therapeutisches System zur Anwendung von Sildenafil
HK1040921B (en) * 1998-12-23 2005-12-30 Alza Corporation Dosage forms comprising porous particles
IL139457A0 (en) * 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
CN1277021A (zh) * 2000-06-20 2000-12-20 王建华 一种治疗阳痿病的喷雾剂药物及其制备方法
DE10248601B4 (de) * 2002-10-17 2006-05-24 Goldstein, Naum, Dr.habil.nat. Pharmazeutisches Mittel zur endonasalen Applikation bei der Behandlung von Krankheiten und Störungen des zentralen Nervensystems
US7554270B2 (en) * 2003-05-28 2009-06-30 Tokyo Ohka Kogyo Co., Ltd. Composition for dielectric of plasma display panel, laminate for dielectric, and method for forming the dielectric
WO2005077374A1 (en) 2004-02-06 2005-08-25 Becton, Dickinson And Company Formulations of phosphodiesterase 5 inhibitors and methods of use
CA2575684A1 (en) * 2004-08-23 2006-03-02 Mannkind Corporation Pulmonary delivery of inhibitors of phosphodiesterase type 5
KR20080083188A (ko) * 2006-01-11 2008-09-16 아스트라제네카 아베 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도
RU2009104151A (ru) * 2006-08-02 2010-09-10 Вм. Ригли Дж. Компани (Us) Способ приготовления состава и состав (варианты) для ухода за полостью рта
JP5686978B2 (ja) * 2009-03-18 2015-03-18 第一三共ヘルスケア株式会社 シルデナフィルクエン酸塩含有内服液剤及びその液剤含有容器

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050142069A1 (en) * 1997-10-01 2005-06-30 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
WO2001035926A2 (en) * 1999-11-18 2001-05-25 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
US20070031349A1 (en) * 2005-06-23 2007-02-08 David Monteith Rapidly absorbing oral formulations of PDE 5 inhibitors

Also Published As

Publication number Publication date
AU2012347997A1 (en) 2014-07-03
CN104822368A (zh) 2015-08-05
CA2858364A1 (en) 2013-06-13
KR20140117360A (ko) 2014-10-07
NZ625922A (en) 2015-05-29
IL232970A0 (en) 2014-08-31
CN104822368B (zh) 2019-01-11
BR112014013650A2 (pt) 2017-07-04
EP2787967B1 (en) 2018-10-31
SG11201402938RA (en) 2014-07-30
JP2015500285A (ja) 2015-01-05
US9186321B2 (en) 2015-11-17
HK1199843A1 (en) 2015-07-24
US20150051216A1 (en) 2015-02-19
CA2858364C (en) 2018-07-24
EP2787967A1 (en) 2014-10-15
WO2013085904A1 (en) 2013-06-13
RU2611403C1 (ru) 2017-02-21
JP6047174B2 (ja) 2016-12-21
ZA201404091B (en) 2017-11-29

Similar Documents

Publication Publication Date Title
AU2012347997B2 (en) Oral spray formulations and methods for administration of sildenafil
CA2802047C (en) Oral spray formulations and methods for administration of sildenafil
US12109196B2 (en) Non-sedating dexmedetomidine treatment regimens
US12465598B2 (en) Methods of treating migraine
US20250319069A1 (en) Methods for treating depressive states
HK1199843B (en) Oral spray formulations and methods for administration of sildenafil
NZ625922B2 (en) Oral spray formulations and methods for administration of sildenafil
HK1183818A (en) Oral spray formulations and methods for administration of sildenafil citrate
HK1183818B (en) Oral spray formulations and methods for administration of sildenafil citrate
US20260000650A1 (en) Non-sedating dexmedetomidine treatment regimens

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired